Unique ID issued by UMIN | UMIN000002957 |
---|---|
Receipt number | R000003407 |
Scientific Title | INtraPeritoneal Administration of ChemoTherapeutic agent Trial |
Date of disclosure of the study information | 2009/12/31 |
Last modified on | 2018/01/05 17:19:17 |
INtraPeritoneal Administration of ChemoTherapeutic agent Trial
INPACT trial
INtraPeritoneal Administration of ChemoTherapeutic agent Trial
INPACT trial
Japan |
gastric cancer (large type 3 or type 4 cancer, or cancer with CY1 or P1 status who nevertheless will be treated by gastrectomy)
Gastrointestinal surgery |
Malignancy
NO
This randomized phase II study aims to evaluate a chemotherapeutic regimen involving intraperitoneal paclitaxel against scirrhous type gastric cancer and cases with minimal peritoneal deposits or detactable free cancer cells in the peritoneal cavity.
Efficacy
Exploratory
Phase II
2 year survival rate
toxicity
progression free survival
overall survival
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
YES
Institution is considered as adjustment factor in dynamic allocation.
YES
Central registration
2
Treatment
Medicine |
intraperitoneal paclitaxel administration at 60 mg/m2 on days 0, 14, 21, 28, 42, 49, 56.
intravenous paclitaxel administration at 80 mg/m2 on days 0, 14, 21, 28, 42, 49, 56.
20 | years-old | <= |
Not applicable |
Male and Female
1) Histological diagnosis of adenocarcinoma of the stomach
2) Macroscopically type 3 or type 4, or are suspected to suffer from peritoneal metastasis
3) Macroscopically type 3 will need to exceed 8 cm in diameter either by the endoscopy or double contrast study
4) No bulky nodal metastasis, hepatic , lung metastasis, massive ascites, thoracic effusion, other distant metastasis by computerized tomography
5) No clinical evidence of distant metastasis
6) Previously untreated by chemotherapy or radiation
7) ECOG Performance statsu 0 or 1
8) adequate organ functions
9) No serious arrhythmia on ECG within 3 months of registration
10) Surgery planned less than 1 month ahead
11) Written informed consent obtained
1) Serious cardiac, hepatic, and pulmonary comorbidities or uncontrollable diabetes mellitus. Active gastrointestinal bleeding or bowel obstruction
2) Active second malignancy either found simultaneously or within 5 years from the diagnosis of gastric cancer
3) Suffering from infection
4) Under steroid therapy
5) Has wishes to become pregnant
6) Under mental disorder
7) allergy to the ingredients of paclitaxel injection
8) severe drug allergy
9) Peripheral neural disorder
100
1st name | |
Middle name | |
Last name | Yasuhiro Kodera |
Nagoya University Graduate School of Medicine
Department of Surgery II
65 Tsurumai-cho, Showa-ku, Nagoya, Japan
052-744-2250
ykodera@med.nagoya-u.ac.jp
1st name | |
Middle name | |
Last name | Yasuhiro Kodera |
Nagoya University Graduate School of Medicine
Department of Surgery II
65 Tsurumai-cho, Showa-ku, Nagoya, Japan
0525-744-2249
ykodera@med.nagoya-u.ac.jp
Non profit organization ECRIN
Non profit organization ECRIN
Non profit foundation
NO
名古屋大学付属病院(愛知県)
近畿大学付属病院(大阪府)
東京慈恵会医科大学附属柏病院(千葉)
東京慈恵会医科大学附属病院(東京都)
神奈川県立がんセンター(神奈川県)
愛知県がんセンター(愛知県)
千葉県がんセンター(千葉県)
市立伊丹病院(大阪府)
金沢医科大学付属病院(石川県)
兵庫県立淡路病院(兵庫県)
群馬大学医学部付属病院(群馬県)
九州大学付属病院(福岡県)
2009 | Year | 12 | Month | 31 | Day |
Partially published
Intraperitoneal administration of paclitaxel was safely conducted with minimal adverse events.
However, there was no significant difference in progression-free survival and overall survival between the two arms.
Completed
2009 | Year | 09 | Month | 01 | Day |
2009 | Year | 10 | Month | 01 | Day |
2016 | Year | 12 | Month | 31 | Day |
2017 | Year | 09 | Month | 27 | Day |
2017 | Year | 11 | Month | 02 | Day |
2017 | Year | 12 | Month | 19 | Day |
2009 | Year | 12 | Month | 30 | Day |
2018 | Year | 01 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003407